Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 3/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283144 | 0.98 | P2RY14 (0.48) | P2RY14MAPK14CNR2CNR1CRHR1 | |
| SCHEMBL283367 | 0.87 | CNR2 (0.60) | CNR2 | |
| SCHEMBL17713941 | 0.85 | CNR2 (0.57) | P2RY14MAPK14CNR2CRHR1CRHR2 | |
| SCHEMBL2813991 | 0.84 | CNR2 (0.46) | MAPK14CNR2CNR1CRHR1CRHR2 | |
| SCHEMBL283719 | 0.82 | RET (0.41) | P2RY14MAPK14CNR2CNR1 | |
| SCHEMBL283889 | 0.82 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL283574 | 0.82 | RET (0.40) | P2RY14MAPK14CNR2CNR1 | |
| SCHEMBL284405 | 0.81 | CNR2 (0.45) | P2RY14MAPK14CNR2CNR1 | |
| SCHEMBL283706 | 0.81 | NPSR1 (0.55) | P2RY14 | |
| SCHEMBL283651 | 0.78 | MAPK14 (0.49) | P2RY14MAPK14MAPK13HTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| CN-102216277-A | Substituted benzamides as cannabinoid receptor ligands | ABBOTT LAB | 2011-10-12 | — | — | CN | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | P2RY14 169/4885MAPK14 2205/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.